Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

UBS Downgrades Purple Innovation to Neutral

UBS downgrades Purple Innovation (NASDAQ:PRPL) from Buy to Neutral.

byBenzinga Newsdesk

November 10, 2021

1 minute read

UBS downgrades Purple Innovation (NASDAQ:PRPL) from Buy to Neutral.

ATyr Pharma’s Lead Candidate Shows Promise In Inflammatory Lung Disease

By Vandana Singh

Today, 4:55 AM

ATyr Pharma Inc (NASDAQ:LIFE) has announced positive results from its Phase 1b/2a trial evaluating its lead therapeutic candidate, ATYR1923, in pulmonary…

LIFE

Earnings Scheduled For December 23, 2021

By Benzinga Insights

Today, 4:55 AM

Companies Reporting Before The Bell • MOGU (NYSE:MOGU) is projected to report earnings for its second quarter. This article was generated by Benzinga's automated content engine and reviewed by an editor.

MOGU

FDA
News

Ironwood Pharmaceuticals Announces FDA Approval of Revised LINZESS Label

By Benzinga Newsdesk

Today, 4:55 AM

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a GI-focused healthcare company, today announced that the U.S. Food and Drug Administration (FDA) approved a revised label for LINZESS® (linaclotide) based on

IRWD

Merchants Bancorp Q3 EPS $1.22, Inline, Sales $114.57M Miss $115.15M Estimate

By Benzinga Newsdesk

Today, 4:55 AM

Merchants Bancorp (NASDAQ:MBIN) reported quarterly earnings of $1.22 per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported quarterly sales of $114.57

MBIN

UBS Downgrades Purple Innovation to Neutral

Related Posts

ATyr Pharma’s Lead Candidate Shows Promise In Inflammatory Lung Disease

Earnings Scheduled For December 23, 2021

Ironwood Pharmaceuticals Announces FDA Approval of Revised LINZESS Label

Merchants Bancorp Q3 EPS $1.22, Inline, Sales $114.57M Miss $115.15M Estimate